Table 2.
Comparison among patients’ demographic and clinical characteristics (overall, enrolled patients, and patients who declined participation).
| Total (n = 760) |
Declined (n = 404) |
Accepted (n = 356) |
p-Value | ||
|---|---|---|---|---|---|
| Age (years), median (IQR) | 66 (60–71) | 66 (60–71) | 65 (59–71) | 0.48 § | |
| History of PCa, n (%) | No | 675 (88.8%) | 351 (86.9%) | 324 (91.0%) | 0.071 * |
| Yes | 85 (11.2%) | 53 (13.1%) | 32 (9.0%) | ||
| Pre-biopsy PSA (ng/mL), median (IQR) | 7.01 (5.11–11.06) | 6.795 (5–10.21) | 7.675 (5.2–12.4) | 0.016 § | |
| PIRADS, n (%) | 1 | 33 (4.3%) | 29 (7.2%) | 4 (1.1%) | <0.001 * |
| 2 | 1 (0.1%) | 1 (0.2%) | 0 (0.0%) | ||
| 3 | 95 (12.5%) | 65 (16.1%) | 30 (8.4%) | ||
| 4 | 201 (26.4%) | 109 (27.0%) | 92 (25.8%) | ||
| 5 | 80 (10.5%) | 23 (5.7%) | 57 (16.0%) | ||
| N.A. | 350 (46.1%) | 177 (43.8%) | 173 (48.6%) | ||
| Prostate volume at MRI (cc), median (IQR) | 50 (36–70) | 56 (42–74) | 48 (35–66) | 0.014 § | |
| ISUP at final histological report, n (%) | 1 | 16 (2.1%) | 11 (2.7%) | 5 (1.4%) | 0.004 * |
| 2 | 127 (16.7%) | 53 (13.1%) | 74 (20.8%) | ||
| 3 | 78 (10.3%) | 23 (5.7%) | 55 (15.4%) | ||
| 4 | 22 (2.9%) | 4 (1.0%) | 18 (5.1%) | ||
| 5 | 36 (4.7%) | 9 (2.2%) | 27 (7.6%) | ||
| N.A. | 481 (63.3%) | 304 (75.2%) | 177 (49.7%) | ||
| pT, n (%) | 2a | 29 (3.8%) | 10 (2.5%) | 19 (5.3%) | 0.21 * |
| 2b | 2 (0.3%) | 1 (0.2%) | 1 (0.3%) | ||
| 2c | 148 (19.5%) | 62 (15.3%) | 86 (24.2%) | ||
| 3a | 71 (9.3%) | 21 (5.2%) | 50 (14.0%) | ||
| 3b | 29 (3.8%) | 6 (1.5%) | 23 (6.5%) | ||
| N.A. | 481 (63.3%) | 304 (75.2%) | 177 (49.7%) | ||
| pN, n (%) | 0 | 199 (26.2%) | 77 (19.1%) | 122 (34.3%) | 0.076 * |
| 1 | 28 (3.7%) | 6 (1.5%) | 22 (6.2%) | ||
| N.A. | 533 (70.1%) | 321 (79.5%) | 212 (59.6%) | ||
| Positive margins (R), n (%) | 0 | 228 (30.0%) | 85 (21.0%) | 143 (40.2%) | 0.29 * |
| 1 | 51 (6.7%) | 15 (3.7%) | 36 (10.1%) | ||
| N.A. | 481 (63.3%) | 304 (75.2%) | 177 (49.7%) | ||
| % of tumor, median (IQR) | 15 (8–20) | 10 (5–20) | 15 (10–25) | 0.017 § | |
| EPE, n (%) | No | 211 (27.8%) | 78 (19.3%) | 133 (37.4%) | 0.49 * |
| Yes | 68 (8.9%) | 22 (5.4%) | 46 (12.9%) | ||
| N.A. | 481 (63.3%) | 304 (75.2%) | 177 (49.7%) |
§ Wilcoxon rank-sum test; * Pearson’s chi-squared test; EPE: extra-prostatic extension; ISUP: International Society of Urological Pathology; PCa: prostate cancer; IQR: interquartile range; PIRADS: Prostate Imaging Reporting And Data System; MRI: magnetic resonance imaging; N.A.: not available. Parameters for which a statistically significant difference is present are bolded.